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For millennia, Plasmodium falciparum malaria has exerted signiﬁcant
evolutionary pressure on the human genome, selecting for balanced
polymorphisms that confer disease protection. This possibility was
ﬁrst proposed in 1949 by J. B. S. Haldane, who suggested that reduced
ﬁtness in β-thalassemia homozygotes due to severe anemia was offset
by increased ﬁtness in heterozygotes due to P. falciparum malaria
protection (Haldane, 1949). In 1954, A. S. Allison demonstrated in
Kenya that hemoglobin S (HbS) heterozygosity (HbAS, sickle-cell
trait) conferred protection frommalaria, and proposed that this protec-
tion balanced the severe anemia morbidity and premature fatality
associated with HbS homozygosity (HbSS, sickle-cell disease) (Allison,
1954). Clinical studies have since associated HbC and α+thalassemia
with malaria protection (Williams, 2006; Taylor et al., 2012), and
shown that α+thalassemia antagonizes HbAS; that is, HbAS children
who co-inherit α+thalassemia are not protected from malaria
(Williams et al., 2005).
While the mechanisms by which hemoglobinopathies confer malaria
protection are debated (Taylor et al., 2013), with the notable exception
of HbAS, they do not seem to protect by suppressing parasite densities.
Epidemiological observations, together with in-vitro data, support alter-
native mechanisms of protection that enable individuals to “tolerate”
parasitemia without developing symptoms. In one mechanism, HbS
and α+thalassemia each impairs binding of parasitized red blood cells
(pRBCs) to microvascular endothelial cells (MVECs, cytoadherence) and
uninfected RBCs (rosetting), two virulence traitsmediated by interactions
between P. falciparum erythrocytemembrane protein 1 (PfEMP1) ligands
on pRBCs and various receptors (CD36, ICAM1, endothelial protein C re-
ceptor [EPCR]) on host cells. We have always believed that future exper-
imental data consistent with this mechanism are more likely to be
biologically and clinically relevant if they reconcilewith robust epidemio-
logical ﬁndings.
In this issue of EBioMedicine, Opi et al. (2014) meet exactly this type
of criterion in proposing a mechanism to explain their original 2005
report of negative epistasis between α+thalassemia and HbAS in
Kenya (Williams et al., 2005). Speciﬁcally, they hypothesized thatDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.10.006.
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the ﬁeld, then it should also antagonize cytoadherence-weakening
effects of HbAS in the laboratory. Using RBCs from individuals with
HbAS, α+thalassemia, or both, they performed experiments that
measure cytoadherence, rosetting, and PfEMP1 expression of four
P. falciparum lines. While their reductionist approach of using few
parasite strains is a minor limitation of this study, they made up
for this by using a large panel of RBCs from hemoglobinopathic do-
nors (10–20 of each genotype) (Opi et al., 2014). Their ﬁndings
largely conﬁrm earlier reports that HbAS and α+thalassemia are
each associated with impaired cytoadherence, rosetting, and
PfEMP1 expression (Cholera et al., 2008; Krause et al., 2012), with
two exceptions. For one parasite strain, α+thalassemia increased
PfEMP1 expression without affecting rosetting; for another, α-
+thalassemia increased PfEMP1 expression but paradoxically de-
creased cytoadherence.
These ﬁndings contrast with those of Krause et al. (2012), who gen-
erally found that α+thalassemia reduced both PfEMP1 expression and
cytoadherence (α+thalassemia increased the cytoadherence of some
parasite isolates) (see Fig. 1A–B of reference Krause et al., 2012).
These apparent discrepancies may result from marked differences in
the authors' use of (i) antibodies speciﬁc for PfEMP1 variants expressed
by parasite lines ITvar9 and TM284var1 (vs. FVO, A4tres, and FCR3CSA);
(ii) four laboratory-adapted parasite lines (vs. multiple naturally-
circulating parasite isolates from Malian children with malaria); and
(iii) puriﬁed CD36 and ICAM1 proteins as binding substrates
(vs. CD36-expressing MVECs and monocytes). As Opi et al. (2014)
emphasize, future studies should test large numbers of both RBC do-
nors and P. falciparum strains to help resolve these differences,
which will hopefully provide more consistent experimental data
that adequately explain well-established ﬁeld observations in
Africa (reviewed in Taylor et al., 2012). These differences notwith-
standing, themajor new ﬁnding of this study is thatα+thalassemia con-
sistently reverses HbAS-mediated reductions in cytoadherence, rosetting,
and PfEMP1 expression in vitro.
This solid result now provides impetus for exploring how
α+thalassemia antagonizes the effects of HbAS on PfEMP1-mediated
phenomena. One possibility is that α+thalassemia selectively reduces
the amount of HbS in HbAS RBCs, for example, by reducing the number
of α-globins that bind βs globins to form stable hemoglobin α2β2 tetra-
mers. Opi et al. (2014) provide preliminary evidence to support this,
showing that the proportion of intracellular HbS signiﬁcantly decreases
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tions correlate with cytoadherence, rosetting, PfEMP1 expression, and
“knob” densities (Cholera et al., 2008) remains to be determined.
Nevertheless, this study further highlights in-vitro binding assays
as valuable tools in deﬁninghowhemoglobinopathies confermalaria pro-
tection. Additional experiments using naturally-circulating isolates and
hemoglobinopathic RBCs from areas where α+thalassemia is common
are needed to conﬁrm this study's ﬁndings, to investigate the lack of
epistasis between α+thalassemia and HbC in clinical studies (reviewed
in Taylor et al., 2012), and the effects of α+thalassemia and HbAS on
pRBC binding to EPCR — a phenotype strongly associated with cerebral
malaria syndromes that are rarely seen in HbAS children.
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